PULSE BIOSCIENCES, INC. Annual Report - A Deep Dive for Investors (Fiscal Year 2025)

For investors tracking PULSE BIOSCIENCES, INC. (PLSE), the fiscal year 2025 marks a pivotal period. This summary cuts through the technical details to provide a clearer, more actionable understanding of the company's financial health, strategic direction, and the challenges it faces. Our goal is to help you assess if this innovative medical device company aligns with your investment strategy.

Business Overview: PULSE BIOSCIENCES' Mission and 2025 Progress

PULSE BIOSCIENCES develops medical devices using its proprietary Nano-pulse Stimulation (NPS) technology. This innovative platform delivers ultra-short electrical pulses to target specific cells without harming surrounding tissue. The technology holds promise for various medical applications, including dermatology and cardiac ablation.

The company's product pipeline features devices such as CellFX, Vybrance, nPulse, nsPFA, and nano-PFA, indicating a strategic focus on both aesthetic and therapeutic uses.

Fiscal year 2025 was a transformative year, characterized by significant investment in product development and the initial steps toward commercialization. PULSE BIOSCIENCES is actively shifting from a pure research and development (R&D) phase to preparing its products for market entry, a transition reflected in its evolving cost structure.

Financial Performance: The Numbers Tell a Story of Investment

PULSE BIOSCIENCES' financial snapshot for 2025 clearly shows a company in a heavy investment phase. While spending significantly increased, the company reported no substantial revenue.

• Revenue: PULSE BIOSCIENCES generated no significant revenue from product sales in 2025. This indicates the company remains pre-commercial or in the very early stages of market penetration, relying on capital raises to fund its operations.
• Cost of Sales: For the first time, PULSE BIOSCIENCES reported $1.5 million in Cost of Sales in 2025, a notable increase from $0 in 2024. This expense signals the production of actual devices, moving the company beyond pure research and development.
• Research and Development (R&D): The company significantly increased its R&D investment, which surged to $6 million in 2025 from $0 in 2024. This reflects its strong commitment to advancing NPS technology and expanding its product pipeline.
• Selling, General, and Administrative (SG&A) Expenses: These crucial costs, which support sales infrastructure and marketing, doubled to $10 million in 2025 from $5 million in 2024. This jump suggests the company is actively building out its commercial team and preparing for market launches.
• General and Administrative (G&A) Expenses: Core administrative overhead quadrupled to $12 million in 2025 from $3 million in 2024. This substantial increase points to expanded corporate infrastructure, as well as rising legal and compliance costs associated with growing operations and commercialization efforts.
• Net Loss: With substantial expenses and no reported revenue, the company incurred a significant net loss in 2025. Combined operational expenses (Cost of Sales, R&D, SG&A, G&A) totaled approximately $29.5 million for the year. This high burn rate highlights the ongoing need for continuous funding.

Management Discussion (MD&A Highlights)

Management's discussion emphasizes the strategic shift from an R&D-centric model to active commercialization. The significant increases in Cost of Sales, R&D, SG&A, and G&A expenses directly reflect this transition, representing investments in manufacturing, clinical development, regulatory submissions, and building a commercial infrastructure. Management stresses the critical need for continued capital to sustain these operations and advance products through regulatory pathways to market. They highlight successful capital raises in 2024 as crucial steps in funding these strategic initiatives, while also acknowledging the ongoing requirement for additional financing.

Financial Health & Liquidity

PULSE BIOSCIENCES concluded 2025 with approximately $6 million in cash and cash equivalents, a positive increase from $0 in 2024. This improved cash position resulted primarily from successful capital raises in 2024, including a Rights Offering (allowing existing shareholders to buy more shares) and an At-the-Market (ATM) Offering (issuing new shares directly into the market). These offerings provided the necessary funds to fuel R&D and commercialization efforts.

However, the company explicitly states its critical need for "additional funding to finance our operations and complete the development and commercialization of our products." This indicates that despite its current cash balance, the significant burn rate means PULSE BIOSCIENCES anticipates requiring more capital in the near future to sustain operations and bring its products to market. The summary does not mention significant long-term debt, suggesting the company's funding strategy relies heavily on equity raises.

Future Outlook (Guidance, Strategy)

PULSE BIOSCIENCES is clearly focused on bringing its NPS technology to market. Its strategy involves continued heavy investment in R&D to expand product indications and enhance existing devices, alongside building a robust commercial infrastructure.

• Commercialization Strategy: The increase in SG&A suggests the company is developing a direct sales force or partnership model to launch products like CellFX. Identifying specific target markets (e.g., dermatology, cardiology) will be key.
• Regulatory Pathway: The company's future success hinges on successfully navigating regulatory processes. Timely FDA and non-U.S. approvals are critical milestones.
• Product Pipeline Progression: Investors should expect continued updates on clinical trials and regulatory submissions for the company's various NPS-based devices.

Competitive Position

The medical device industry, particularly in aesthetics and therapeutic ablation, is highly competitive and rapidly evolving. PULSE BIOSCIENCES operates within this landscape, competing with established companies and emerging technologies that offer alternative treatments. Key competitive factors typically include product efficacy and safety, regulatory status, intellectual property protection, clinical data, commercialization capabilities, pricing, and reimbursement.

The company's primary competitive advantage stems from its proprietary Nano-pulse Stimulation (NPS) technology. PULSE BIOSCIENCES believes NPS offers unique benefits, such as precise cell targeting with minimal damage to surrounding tissue.

Key Risks for Investors

Beyond general market risks, investors in PULSE BIOSCIENCES should pay close attention to:

1. Funding and Dilution Risk: The company's explicit need for future funding is paramount. Investors should anticipate potential equity raises that could dilute their ownership and impact share price.
2. Regulatory Approval Risk: Delays or failures in obtaining necessary regulatory clearances for their devices could severely impact the company's ability to generate revenue and achieve commercial success.
3. Clinical Trial Risk: The success of their products depends on positive clinical trial outcomes, which are never guaranteed. Unfavorable results could delay or prevent market entry.
4. Commercialization and Market Adoption Risk: Even with approved products, achieving successful market penetration, physician training, and patient acceptance presents significant challenges. Factors like competition, pricing pressures, and reimbursement policies could hinder adoption.
5. Intellectual Property Risk: Protecting its proprietary NPS technology through patents is vital for long-term competitive advantage. Challenges to these patents or the inability to obtain new patents could weaken the company's market position.
6. Product Liability Risk: As a medical device company, PULSE BIOSCIENCES faces inherent risks related to product defects or failures that could lead to patient injury, costly litigation, and reputational damage.
7. Dependence on Key Personnel: The company's success relies heavily on the expertise and continued service of its key management, scientific, and technical personnel.

In summary, PULSE BIOSCIENCES is an innovative company with promising technology, but it remains in a high-growth, high-expenditure phase. Its financial performance in 2025 highlights significant investment and progress towards commercialization, alongside a substantial cash burn and a clear reliance on future capital raises. Investors should carefully weigh the potential of its NPS technology against the inherent risks of a pre-revenue or early-commercialization stage medical device company.